- Home
- BVC vs OLMA Comparison
BVC vs OLMA Comparison
Compare BVC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BVC | OLMA |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BVC | OLMA |
|---|---|---|
| Price | $10.25 | $16.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $44.89 |
| AVG Volume (30 Days) | 2.5K | ★ 966.8K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $3.89 |
| 52 Week High | $15.00 | $36.26 |
Technical Indicators
Market Signals| Indicator | BVC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 51.29 |
| Support Level | $8.05 | $13.11 |
| Resistance Level | $11.62 | $16.99 |
| Average True Range (ATR) | 0.55 | 0.76 |
| MACD | 0.00 | 0.50 |
| Stochastic Oscillator | 65.81 | 92.06 |
Price Performance
Historical ComparisonAbout BVC BitVentures Limited American Depositary Shares
BitVentures Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. The Company is developing technology businesses in verticals including e-commerce, digital assets, consumer healthcare, and other areas of consumer.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.